Loading organizations...

§ Private Profile · Vienna, Wien, Austria
Themis Bioscience is a technology company.
Themis Bioscience has raised $74.1M across 4 funding rounds.
Key people at Themis Bioscience.
Themis Bioscience has raised $74.1M in total across 4 funding rounds.
Themis Bioscience developed vaccines for infectious diseases using a proprietary measles virus vector-based platform technology. This innovative approach enabled the creation of immunotherapies for various indications, with their lead product being a vaccine candidate against the tropical disease Chikungunya. The company’s platform demonstrated promise for rapid adaptation to new threats, including its potential application in developing a vaccine for COVID-19.
The company was co-founded in 2009 in Vienna, Austria, by Dr. Erich Tauber, who served as its CEO. Dr. Tauber, a pediatrician and Associate Professor of Clinical Pharmacology, established Themis based on a technology platform originally developed at the Institut Pasteur, which the company licensed in 2010. This foundational insight centered on leveraging a well-understood viral vector for targeted vaccine development.
Themis Bioscience’s primary focus was on developing products to protect human populations from infectious diseases, particularly those with unmet medical needs. The company envisioned a future where its versatile vaccine platform could contribute significantly to global health security. Its eventual acquisition by Merck expanded the potential reach and impact of its technologies on a worldwide scale.
Themis Bioscience is a Vienna‑based biotechnology company that developed a proprietary measles‑virus vector platform to make vaccines and oncolytic/immunomodulatory therapies for infectious diseases and cancer; the company progressed multiple candidates (Chikungunya, Lassa, Zika and oncology programs) and entered collaborations with MSD/Merck and CEPI before being acquired by Merck (MSD) in 2020–2021 to integrate its measles‑vectored vaccine and immuno‑oncology capabilities into a larger vaccine and infectious‑disease development effort[1][2][3].
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech / Biotech Landscape
Quick Take & Future Outlook
Quick take: Themis built a scientifically credible, academically rooted measles‑virus vector platform that proved commercially and strategically attractive—its clinical progress and high‑profile partnerships made it a logical acquisition target for a major vaccine company seeking platform breadth and outbreak‑response capabilities[1][2][3].
Themis Bioscience has raised $74.1M in total across 4 funding rounds.
Themis Bioscience's investors include Farallon Capital Management, Walter Stockinger, Adjuvant Capital, IST cube, aws Gruenderfonds, Global Health Investment Fund, MSD, Omnes Capital, Ventech, Wellington Partners, Glenn Rockman, Credit Agricole Private Equity.
Key people at Themis Bioscience.
Themis Bioscience has raised $74.1M across 4 funding rounds. Most recently, it raised $44.0M Series D in September 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2019 | $44M Series D | Farallon Capital Management, Walter Stockinger | Adjuvant Capital, IST Cube, AWS Gruenderfonds, Global Health Investment Fund, MSD, Omnes Capital, Ventech, Wellington Partners | Announced |
| Jan 1, 2018 | $12M Series C | Glenn Rockman | Adjuvant Capital, IST Cube, AWS Gruenderfonds, Omnes Capital, Ventech, Wellington Partners | Announced |
| Nov 1, 2016 | $11M Series B | — | IST Cube | Announced |
| May 21, 2011 | $7.1M Series A | Credit Agricole Private Equity, Ventech | — | Announced |